Interestingly, myricetin exerts its insulin secretory potential in a dose-dependent manner exclusively at the stimulatory glucose concentration, suggesting a reduction in the hypoglycemia and other adverse effects caused by already marketed drugs like sulfonylurea and glinide. This evidence concerns the gene INS and Hypoglycemia.